KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Non-Current Deffered Revenue (2018 - 2023)

Astrazeneca has reported Non-Current Deffered Revenue over the past 6 years, most recently at $7.0 million for Q4 2023.

  • For Q4 2023, Non-Current Deffered Revenue fell 50.0% year-over-year to $7.0 million; the TTM value through Dec 2023 reached $7.0 million, down 50.0%, while the annual FY2023 figure was $7.0 million, 50.0% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2023 was $7.0 million at Astrazeneca, down from $14.0 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $50.0 million in Q4 2019 and troughed at $7.0 million in Q4 2023.
  • A 5-year average of $27.0 million and a median of $26.0 million in 2021 define the central range for Non-Current Deffered Revenue.
  • Biggest five-year swings in Non-Current Deffered Revenue: dropped 24.0% in 2020 and later plummeted 50.0% in 2023.
  • Year by year, Non-Current Deffered Revenue stood at $50.0 million in 2019, then dropped by 24.0% to $38.0 million in 2020, then plummeted by 31.58% to $26.0 million in 2021, then crashed by 46.15% to $14.0 million in 2022, then plummeted by 50.0% to $7.0 million in 2023.
  • Business Quant data shows Non-Current Deffered Revenue for AZN at $7.0 million in Q4 2023, $14.0 million in Q4 2022, and $26.0 million in Q4 2021.